早期多西他赛联合恩扎卢胺治疗转移性激素敏感性前列腺癌的目标试验模拟
本研究利用ENZAMET试验数据,采用目标试验模拟方法评估在恩扎卢胺基础上加用早期多西他赛对转移性激素敏感性前列腺癌(mHSPC)总生存(OS)的影响。匹配987例患者后,计划使用早期多西他赛与否OS相似(HR 1.02,95%CI 0.92-1.12;P=0.72),但恩扎卢胺使用存在效应修饰(交互P=0.02)。结论:早期多西他赛不改善恩扎卢胺治疗者的生存,不支持常规联合。
要点
- 在恩扎卢胺治疗者中,加用早期多西他赛未改善OS(HR 1.18,95%CI 0.94-1.49)。
- 未用恩扎卢胺者中,早期多西他赛延长OS(HR 0.90,95%CI 0.82-0.98),高瘤负荷更明显。
- 结果不支持在mHSPC中常规将早期多西他赛加入恩扎卢胺。
核心结论
- 早期多西他赛加入恩扎卢胺未改善mHSPC患者OS,无论疾病体积。
- 未使用恩扎卢胺时,早期多西他赛改善OS,尤其高瘤负荷患者。
研究设计与样本
- 基于ENZAMET随机试验(1125例mHSPC)的目标试验模拟研究。
- 采用倾向性评分匹配模拟四种治疗比较,匹配987例(87.7%)。
- 使用Cox比例风险回归评估OS。
主要发现
- 匹配后计划使用早期多西他赛与否OS相似(HR 1.02,95%CI 0.92-1.12;P=0.72)。
- 恩扎卢胺使用对多西他赛效应有修饰作用(交互P=0.02)。
- 恩扎卢胺组中加用多西他赛OS相似(HR 1.18,95%CI 0.94-1.49),不受疾病体积影响(交互P=0.37)。
- 非恩扎卢胺组中早期多西他赛延长OS(HR 0.90,95%CI 0.82-0.98),高瘤负荷交互P=0.006。
关键数值与推荐
- 匹配队列987例(87.7%),基线特征均衡。
- 恩扎卢胺组加用多西他赛HR 1.18(95%CI 0.94-1.49)。
- 非恩扎卢胺组加用多西他赛HR 0.90(95%CI 0.82-0.98)。
临床怎么用
- mHSPC患者使用恩扎卢胺时,不应常规加用早期多西他赛。
- 未使用恩扎卢胺的患者,尤其高瘤负荷,可考虑早期多西他赛。
局限性
- 可能存在残余混杂,不能排除。
- 为目标试验模拟,非直接随机比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To apply a trial emulation method using the 'ENZAlutamide in first line androgen deprivation therapy for METastatic prostate cancer' (ENZAMET) trial data to assess the effects of adding early docetaxel to enzalutamide on overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), as the benefits of adding early docetaxel to novel androgen-receptor pathway inhibitors (ARPIs) are unclear. PATIENTS AND METHODS: The ENZAMET trial randomised 1125 patients with mHSPC to testosterone suppression plus enzalutamide or standard non-steroidal antiandrogen therapy. Investigators indicated at pre-randomisation if they planned to use early docetaxel. We emulated randomised comparisons of four treatments: (i) docetaxel plus enzalutamide, (ii) no docetaxel plus enzalutamide, (iii) docetaxel plus no enzalutamide, and (iv) no docetaxel plus no enzalutamide. Propensity score matching was applied to mitigate selection bias. OS was evaluated using Cox proportional hazards regression. RESULTS: Among 987 matched participants (87.7%), baseline characteristics were balanced. OS was similar with or without planned use of early docetaxel (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92-1.12; P = 0.72), with effect modification by enzalutamide use (interaction P = 0.02). Among those assigned enzalutamide, OS was similar according to the planned use of early docetaxel or not (HR 1.18, 95% CI 0.94-1.49), regardless of disease volume (interaction P = 0.37). Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease (interaction P = 0.006). CONCLUSION: Early docetaxel did not appear to improve survival when added to enzalutamide, regardless of disease volume, whereas it did appear to improve survival when enzalutamide was not used, particularly in high-volume disease. While residual confounding could not be excluded, these findings do not support the routine addition of early docetaxel to enzalutamide in mHSPC.
引用
- Soon YY, Marschner IC, Schou IM, et al. Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU Int. 2025. PMID: 41190384. doi:10.1111/bju.70065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。